Durable responses and improved survival rates with programmed cell death-1 (PD-1)-inhibitors have been observed in malignant melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma and bladder cancer [4–6], changing the therapeutic field in these cancer types significantly. This evidence concerns the gene PDCD1 and urinary bladder carcinoma.